Vermillion, Inc. is engaged in the discovery, development and commercialization of medical tests that help physicians diagnose, treat and improve outcomes for patients with gynecologic cancers and related diseases. The Company’s tests are intended to detect, characterize and stage disease, and to help guide decisions regarding prognosis and patient treatment. The Company’s lead product is OVA1, is an ovarian cancer test system that integrates a software algorithm and blood test. It addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. OVA1 measures the levels of five proteins found in the blood and then uses software called OvaCalc to calculate a single score. A woman’s risk of cancer is measured by using a 0-10 scale versus predetermined cut-off points. Women who are pre-menopausal have a cut off of 5.0 whereas postmenopausal women have a 4.4 cutoff.